Ubrogepant
What is Ubrogepant?[edit | edit source]
Ubrogepant (UBRELVY) is a calcitonin gene-related peptide receptor antagonist used for the acute treatment of migraine attacks with or without aura in adults.
What are the uses of this medicine?[edit | edit source]
How does this medicine work?[edit | edit source]
- Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients who:
- use strong CYP3A4 inhibitors.
What drug interactions can this medicine cause?[edit | edit source]
- UBRELVY should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).
- Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice).
- In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort), loss of ubrogepant efficacy is expected, and concomitant use should be avoided.
- Dose adjustment is recommended with concomitant use of UBRELVY and moderate or weak CYP3A4 inducers
- Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant. Clinical drug interaction studies with inhibitors of these transporters were not conducted.
- Dose adjustment is recommended with BCRP and/or P-gp only inhibitor.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2019.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.
- If needed, a second dose may be taken at least 2 hours after the initial dose.
- The maximum dose in a 24-hour period is 200 mg.
- The safety of treating more than 8 migraines in a 30-day period has not been established.
Administration
- Take UBRELVY exactly as your healthcare provider tells you to take it.
- Take UBRELVY with or without food.
- Most patients can take a second tablet 2 hours after the first tablet, as needed.
- You should not take a second tablet within 24 hours if you consume grapefruit or grapefruit juice or are taking medications that may include:
verapamil cyclosporine ciprofloxacin fluconazole fluvoxamine
- It is not known if it is safe to take UBRELVY for more than 8 migraine headaches in 30 days.
- You should write down when you have headaches and when you take UBRELVY so you can talk to your healthcare provider about how UBRELVY is working for you.
- If you take too much UBRELVY, call your healthcare provider or go to the nearest hospital emergency room right away.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Tablets: 50 mg and 100 mg
This medicine is available in fallowing brand namesː
- UBRELVY
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- nausea and sleepiness
What special precautions should I follow?[edit | edit source]
Do not take UBRELVY if you are taking medicines known as a strong CYP3A4 inhibitor, such as:
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women.
Can this medicine be used in children?[edit | edit source]
- Safety and effectiveness in pediatric patients have not been established.
What are the active and inactive ingredients in this medicine?[edit | edit source]
- Active ingredient: ubrogepant
- Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.
Who manufactures and distributes this medicine?[edit | edit source]
- Manufactured by: Forest Laboratories Ireland Ltd.,
Dublin, Ireland Distributed by: Allergan USA, Inc. Madison, NJ 07940
What should I know about storage and disposal of this medication?[edit | edit source]
- Store UBRELVY at room temperature between 68ºF to 77ºF (20ºC to 25ºC).
- Keep UBRELVY and all medicines out of the reach of children.
Ubrogepant Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Deepika vegiraju